AI assistant
ImageneBio, Inc. — Director's Dealing 2021
Mar 26, 2021
34275_dirs_2021-03-25_b69f6fc6-c306-478e-b128-ee4e36e68d36.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-03-25
Reporting Person: Manfredi Mark (Director, President & CEO)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.15 | 2026-08-24 | Common Stock (95305) | Direct | |
| Stock Option (Right to Buy) | $2.94 | 2028-02-19 | Common Stock (158843) | Direct | |
| Stock Option (Right to Buy) | $2.15 | 2028-12-17 | Common Stock (151279) | Direct | |
| Stock Option (Right to Buy) | $4.15 | 2029-03-19 | Common Stock (204529) | Direct | |
| Stock Option (Right to Buy) | $7.87 | 2031-02-11 | Common Stock (929386) | Direct |
Footnotes
F1: This option is fully vested and exercisable as of the date hereof.
F2: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on January 8, 2018.
F3: 25% of this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F4: 25% of this option vested and became exercisable on March 20, 2020, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F5: 25% of this option shall vest and become exercisable on February 12, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.